Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Up 7.9%

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shot up 7.9% during mid-day trading on Wednesday . The stock traded as high as $1.39 and last traded at $1.37, 457,304 shares traded hands during mid-day trading. A decline of 47% from the average session volume of 860,064 shares. The stock had previously closed at $1.27.

Several brokerages recently issued reports on MRNS. HC Wainwright began coverage on Marinus Pharmaceuticals in a report on Tuesday, September 3rd. They issued a “buy” rating and a $5.00 price target for the company. Mizuho lowered their price target on Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating for the company in a report on Tuesday, July 23rd. ValuEngine upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $3.00 price target on shares of Marinus Pharmaceuticals in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Marinus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $10.59.

The stock has a market capitalization of $67.04 million, a price-to-earnings ratio of -1.52 and a beta of 2.90. The firm has a fifty day moving average of $1.34 and a 200-day moving average of $3.31.



Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). On average, analysts expect that Marinus Pharmaceuticals Inc will post -0.94 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. D. E. Shaw & Co. Inc. purchased a new position in Marinus Pharmaceuticals in the 2nd quarter valued at about $76,000. Morgan Stanley boosted its position in Marinus Pharmaceuticals by 1,679.6% in the 2nd quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock valued at $780,000 after buying an additional 177,331 shares during the last quarter. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock valued at $10,737,000 after buying an additional 115,294 shares during the last quarter. BlackRock Inc. boosted its position in Marinus Pharmaceuticals by 7.2% in the 2nd quarter. BlackRock Inc. now owns 3,427,739 shares of the biopharmaceutical company’s stock valued at $14,226,000 after buying an additional 229,811 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Marinus Pharmaceuticals by 1.9% in the 2nd quarter. Northern Trust Corp now owns 548,467 shares of the biopharmaceutical company’s stock valued at $2,276,000 after buying an additional 10,204 shares during the last quarter. 64.26% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Recommended Story: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.